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Bosutinib efficacy and safety in chronic phase chronic
myeloid leukemia after imatinib resistance or intolerance:
Minimum 24-month follow-up
Carlo Gambacorti-Passerini,1* Tim H. Br€ummendorf,2,3 Dong-Wook Kim,4 Anna G. Turkina,5 Tamas Masszi,6
Sarit Assouline,7 Simon Durrant,8 Hagop M. Kantarjian,9 H. Jean Khoury,10 Andrey Zaritskey,11 Zhi-Xiang Shen,12
Jie Jin,13 Edo Vellenga,14 Ricardo Pasquini,15 Vikram Mathews,16 Francisco Cervantes,17 Nadine Besson,18
Kathleen Turnbull,19 Eric Leip,19 Virginia Kelly,19 and Jorge E. Cortes9
Bosutinib is an orally active, dual Src/Abl tyrosine kinase inhibitor for treatment of chronic myeloid leukemia
(CML) following resistance/intolerance to prior therapy. Here, we report the data from the 2-year follow-up of a
phase 1/2 open-label study evaluating the efficacy and safety of bosutinib as second-line therapy in 288 patients
with chronic phase CML resistant (n5 200) or intolerant (n588) to imatinib. The cumulative response rates to
bosutinib were as follows: 85% achieved/maintained complete hematologic response, 59% achieved/maintained
major cytogenetic response (including 48% with complete cytogenetic response), and 35% achieved major
molecular response. Responses were durable, with 2-year estimates of retaining response >70%. Two-year
probabilities of progression-free survival and overall survival were 81% and 91%, respectively. The most common
toxicities were primarily gastrointestinal adverse events (diarrhea [84%], nausea [45%], vomiting [37%]), which
were primarily mild to moderate, typically transient, and first occurred early during treatment. Thrombocytopenia
was the most common grade 3/4 hematologic laboratory abnormality (24%). Outcomes were generally similar
among imatinib-resistant and imatinib-intolerant patients and did not differ with age. The longer-term results of
the present analysis confirm that bosutinib is an effective and tolerable second-line therapy for patients with
imatinib-resistant or imatinib-intolerant chronic phase CML. ClinicalTrials.gov Identifier: NCT00261846.
Am. J. Hematol. 89:732–742, 2014.VC 2014 The Authors American Journal of Hematology Published by Wiley Periodicals, Inc.
 Introduction
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia characterized by the presence in proliferating cells of the Philadelphia chro-
mosome (Ph), a balanced translocation between chromosomes 9 and 22 that results in production of a Bcr-Abl fusion oncoprotein [1]. Currently,
the most frequently used first-line therapy for patients with chronic phase (CP) CML is the Bcr-Abl tyrosine kinase inhibitor (TKI) imatinib [2,3].
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Unfortunately, development of resistance and intolerance represent a
limitation of imatinib treatment [2,4]. The second-generation TKIs
dasatinib and nilotinib have demonstrated efficacy in patients with
CP CML in the first-line setting and as second-line therapy following
imatinib resistance/intolerance [5–12]. However, resistance or intoler-
ance to these second-generation TKIs may occur in some patients
[13,14]. Thus, alternative treatment options are needed for patients
with CP CML resistant or intolerant to available TKIs.
Bosutinib (SKI-606) is an orally active, dual Src and Abl TKI with
minimal activity against platelet-derived growth factor receptor or c-
KIT [15–17]; it has been suggested that inhibition of these enzymes
may be associated with some of the adverse events (AEs) reported
with imatinib [16,18] and dasatinib [19,20] treatment. In preclinical
studies, bosutinib demonstrated potent Bcr-Abl inhibition of
imatinib-resistant CML cell lines and most imatinib-resistant Bcr-Abl
kinase domain mutations, except T315I and V299L [16,21].
Initial reports from the open-label, phase 1/2 trial in patients with
previously treated Ph1 leukemia indicated good clinical activity and
tolerability with oral bosutinib 500 mg/day. Durable hematologic and
cytogenetic responses were observed among patients with CP CML in
the second-line setting after imatinib [22] and third-/fourth-line settings
after prior imatinib plus dasatinib and/or nilotinib [23]. Responses have
also been observed in accelerated phase (AP) and blast phase (BP)
CML [24]. Frequent toxicities observed with bosutinib include gastroin-
testinal symptoms (ie, diarrhea, nausea, vomiting, and abdominal pain),
rash, fatigue, and pyrexia; grade 3/4 hematologic toxicities and liver
function test abnormalities have also been reported [22–24]. The cur-
rent analysis of this phase 1/2 trial provides a 24-month update of
bosutinib as second-line therapy for patients with CP CML and resist-
ance or intolerance to imatinib and no exposure to other TKIs.
 Methods
The study design and eligibility criteria have been previously described [22–24]. The
current analysis included patients aged 18 years with CP CML and resistance to prior
imatinib 600 mg/day or intolerance to any dose of imatinib who had no previous
exposure to other TKIs; an Eastern Cooperative Oncology Group Performance Status
score of 0 or 1; adequate bone marrow (imatinib-resistant patients), hepatic, and renal
function; 7 days since any prior antiproliferative treatment except for hydroxyurea
and anagrelide; and 3 months postallogeneic hematopoietic stem cell transplant [22].
All patients provided written informed consent before study enrollment.
This was a phase 1/2, open-label, multicenter, 2-part study of bosutinib in
patients with Ph1 leukemias. Part 1 was a dose-escalation study that determined a
recommended phase 2 dose of bosutinib 500 mg/day in patients with CP CML
[22]. Part 2, described in this report, evaluated the efficacy and safety of continued
oral daily dosing of bosutinib at this dose. Dose escalation was allowed for lack of
efficacy (no complete hematologic response [CHR] by week 8 or no complete cyto-
genetic response [CCyR] by week 12) in the absence of grade 3/4 treatment-related
toxicity. Doses could be held or reduced by 100-mg increments to a minimum dose
of 300 mg/day based on the severity and duration of treatment-related toxicities.
Treatment could continue until disease progression (defined as transformation to
AP/BP CML, increased white blood cell count [i.e., doubling occurring over 1
month with the second count >20 3 109/L and confirmed 1 week later], or loss
of previously attained major cytogenetic response [MCyR] or any hematologic
response), unacceptable toxicity (including intolerance to bosutinib 300 mg/day),
or withdrawal of consent. Long-term follow-up continued for 2 years after treat-
ment discontinuation to determine patient-reported progression, initiation of new
anticancer treatment, and survival.
Patients recruited in Part 1 were further analyzed along with patients from Part
2 for both efficacy and long-term safety. The primary endpoint of Part 2 was the
rate of MCyR at week 24 in patients with imatinib-resistant CP CML and has been
previously reported [22]; thus, only cumulative endpoints are reported in the cur-
rent manuscript. Key secondary and exploratory efficacy endpoints included cumu-
lative cytogenetic, hematologic, and molecular response, time to and duration of
response, response by baseline Bcr-Abl kinase domain mutation status, progression-
free survival (PFS), and overall survival (OS).
Response was determined as described previously [22]. Cytogenetic response
assessments were performed every 3 months through 2 years and every 6 months
thereafter during treatment. Additionally, peripheral blood was collected at weeks 1,
2, 3, 4, 8, and 12 for analysis of complete blood cell count and Bcr-Abl transcript
levels (performed monthly) and thereafter was collected on the same schedule as
cytogenetic response assessments. Efficacy endpoints were summarized using
descriptive statistics, cumulative incidence, the Kaplan–Meier method, response
rates, and confidence intervals (CIs). AEs were reported at each study visit through
30 days after the last bosutinib dose; physical examinations, vital signs, and labora-
tory tests were also performed routinely. Additional details of cytogenetic, hemato-
logic, and molecular response assessments and efficacy and safety endpoints are
provided in the Supporting Information.
The protocol was approved by the central or institutional review board for each
study site, and the study was conducted in accordance with the principles of Good
Clinical Practice and the Declaration of Helsinki.
 Results
Patients
Overall, 288 patients with imatinib-resistant (n5 200) or imatinib-
intolerant (n5 88) CP CML were enrolled and treated with bosutinib
in Part 2 of the study, including patients from Part 1 who were enrolled
in Part 2. Patient demographics and baseline disease characteristics
were previously reported [22] and are provided in Supporting Informa-
tion Table SI. Briefly, the median age was 53 years (range, 18–91 years),
with 224 (78%) patients aged <65 years; 153 (53%) patients were male.
The median (range) time since CML diagnosis was 4.0 years (0.1–15.1
years) for imatinib-resistant patients and 2.8 years (0.1–13.6 years) for
imatinib-intolerant patients. The median duration of prior imatinib
treatment was 2.5 years (0.4–8.8 years) for imatinib-resistant patients
and 1.5 years (<0.01–8.3 years) for imatinib-intolerant patients.
As of the data snapshot (March 28, 2011, based on an unlocked data-
base for this interim manuscript), 92 of 200 (46%) imatinib-resistant
patients and 37 of 88 (42%) imatinib-intolerant patients were still receiv-
ing treatment. The most common reasons for treatment discontinuation
included an AE (22%), disease progression (14%), unsatisfactory
response/lack of efficacy (7%), and patient request (6%; Supporting
Information Table SII). The median (range) duration of bosutinib treat-
ment was 22.1 months (0.2–60.8 months). Median follow-up was 30.5
months (0.6–66.0 months) for imatinib-resistant patients and 35.1
months (0.7–58.0 months) for imatinib-intolerant patients; time from
the last enrolled patient’s first visit to the data snapshot in the imatinib-
resistant cohort (primary study cohort) was 24 months (96 weeks).
Three imatinib-intolerant patients with CCyR at their month 21 visit had
not reached their month 24 visit as of the data snapshot but were subse-
quently assessed, with all 3 retaining their CCyR at month 24.
Efficacy
Evaluable patients had received at least 1 dose of bosutinib and
had a valid baseline assessment for the respective endpoint. A total of
85% of evaluable patients either newly achieved a confirmed CHR or
maintained their baseline CHR for 5 weeks, with response rates
being similar between imatinib-resistant and imatinib-intolerant
patients (Table I). Median (range) time to a confirmed CHR among
responders was 2.0 weeks (0.3–72.4 weeks) for imatinib-resistant
patients and 1.7 weeks (0.9–36.3 weeks) for imatinib-intolerant
patients. The cumulative incidence curve for CHR is displayed in
Figure 1A. Of the 141 patients with no CHR at baseline, 109 (77%)
achieved a confirmed CHR.
Among evaluable patients with a valid baseline cytogenetic assess-
ment, 59% newly achieved an MCyR or maintained their baseline
MCyR for 4 weeks, including 58% of imatinib-resistant patients and
61% of imatinib-intolerant patients (Table I). The CCyR rate was 48%.
Median (range) time to MCyR among responders was 12.3 weeks
(4.0–144.0 weeks) for imatinib-resistant patients and 12.1 weeks
(8.0–72.1 weeks) for imatinib-intolerant patients. The cumulative inci-
dence curve for MCyR is displayed in Figure 1B. Nearly all patients
who maintained/achieved an MCyR did so during the first year (Fig.
1C). Among patients without a CCyR at baseline, the MCyR rate was
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57% for imatinib-resistant and imatinib-intolerant patients. The MCyR
and CCyR rates were 53% (95% CI, 47–60) and 43% (95% CI, 37–49),
respectively, when patients with a CCyR at baseline were considered
non-responders.
A major molecular response (MMR; not assessed on the Interna-
tional Scale) was achieved in 35% of treated patients (analysis excluded
patients from China, India, Russia, and South Africa), including 28% of
patients who achieved a complete molecular response, with the propor-
tion of patients who achieved an MMR being similar for imatinib-
resistant (34%) and imatinib-intolerant (35%) patients (Table I).
Median (range) time to MMR among responders was 35.9 weeks (3.1–
172.0 weeks) for imatinib-resistant patients and 12.2 weeks (4.0–144.1
weeks) for imatinib-intolerant patients. The cumulative incidence of
MMR is displayed in Fig. 1D. Among 104 patients who achieved/main-
tained a CCyR and were evaluable for molecular response, 69 (66%;
95% CI, 56–75) patients achieved an MMR.
Responses were durable, with Kaplan–Meier median durations of
CHR, MCyR, and MMR not being reached for imatinib-resistant or
imatinib-intolerant patients (Fig. 2). The 2-year Kaplan–Meier esti-
mates of retaining a response remained >70% in the overall popula-
tion for all three response types, although estimates were generally
higher for imatinib-intolerant versus imatinib-resistant patients.
CHR and MCyR response rates were comparable between older
(aged 65 years) and younger (aged <65 years) patients, as were
Kaplan–Meier estimates of retaining either response at 2 years (65%;
Table II).
A total of 212 patients were assessed for Bcr-Abl kinase domain
mutations at baseline: 79 (37%) patients had 1 mutation, includ-
ing 11 (5%) patients who had 2 mutations. Forty-two unique
point mutations were identified, several of which have been associ-
ated with resistance to imatinib in the clinical setting [25]; the
most frequent mutations were M35IT, F359V, and T315I (n5 9
each). As a whole, patients with 1 mutation had response rates
(CHR, 83%; MCyR, 58%) that were similar to those observed for
patients without baseline mutations (CHR, 90%; MCyR, 59%).
When patients with the T315I mutation were excluded, the
response rates for patients with a mutation were 91% for CHR and
62% for MCyR.
Safety and tolerability
All 288 patients received 1 dose of bosutinib and were included in
the safety population. The most common nonhematologic treatment-
emergent AEs (TEAEs) were gastrointestinal (i.e., diarrhea, nausea,
vomiting, and abdominal pain); rash, pyrexia, fatigue, and increased ala-
nine aminotransferase (ALT) were also commonly observed (Table III).
Diarrhea, rash, and elevated ALT represent the most common grade 3/4
nonhematologic TEAEs, although the incidence of grade 4 events was
low (diarrhea, 0%; rash, 1%; elevated ALT, 1%). The incidences of pleu-
ral effusion (all grades, 5%; grade 3, n5 2; grade 4, n5 1) and pancreati-
tis (all grades, 1%) AEs were low among imatinib-resistant and
imatinib-intolerant patients. Only 3% of patients experienced a pleural
effusion AE considered related to study drug.
Although gastrointestinal AEs (diarrhea, nausea, vomiting) were com-
mon, they were typically of low severity, had an early onset (median
[range] time to first event, 2.0 [1–594] days, 5.0 [1–878] days, and
8.0 [1–1,141] days, respectively), and were generally transient (median
[range] duration, 1.0 [1–574] days, 2.0 [1–446] days, and 1.0 [1–165] days).
Patients with diarrhea were primarily managed with loperamide and/or
diphenoxylate/atropine (69%), and less frequently with temporary
TABLE I. Best Overall Response
Response Imatinib-resistant (n5200) Imatinib-intolerant (n588) Total (n5 288)
Median (range) treatment duration, mo 22.1 (0.2–60.8) 20.7 (0.3–52.3) 22.1 (0.2–60.8)
Cytogenetic response,a n (%) [95% CI]
Evaluable patients 186 80 266
MCyR 108 (58) [51–65] 49 (61) [50–72] 157 (59) [53–65]
CCyR 85 (46) [38–53] 43 (54) [42–65] 128 (48) [42–54]
Evaluable patients without a CCyR at baseline 181 69 250
MCyR 103 (57) [49–64] 39 (57) [44–68] 142 (57) [50–63]
CCyR 80 (44) [37–52] 34 (49) [37–62] 114 (46) [39–52]
Molecular response,b n (%) [95% CI]
Evaluable patients 132 68 200
MMR 45 (34) [26–43] 24 (35) [24–48] 69 (35) [28–42]
CMR 33 (25) [18–33] 22 (32) [22–45] 55 (28) [21–34]
Hematologic response,c n (%) [95% CI]
Evaluable patients 199 88 287
CHR 170 (85) [80–90] 74 (84) [75–91] 244 (85) [80–89]
Evaluable patients without a CHR at baseline 100 41 141
CHR 76 (76) [66–84] 33 (81) [65–91] 109 (77) [70–84]
Abbreviations: CCyR, complete cytogenetic response; CHR, complete hematologic response; CMR, complete molecular response; FISH, fluorescence in situ
hybridization; MCyR, major cytogenetic response; MMR, major molecular response; PCR, polymerase chain reaction; PCyR, partial cytogenetic response;
Ph1, Philadelphia chromosome-positive.
a Evaluable patients must have had an adequate baseline cytogenetic assessment. Cytogenetic response [27] was determined using standard cytogenetics
(G-band karyotype) with 20 metaphases counted for postbaseline assessments; if <20 metaphases were available postbaseline, FISH analysis of bone
marrow aspirate with 200 cells for the presence of Bcr-Abl fusion gene was used. MCyR included PCyR (1–35% Ph1 metaphases) and CCyR (0% Ph1
metaphases; <1% if using FISH). Cytogenetic response could be achieved during the study or maintained from baseline for 4 weeks, unless otherwise
noted within the table.
b Patients enrolled in China, India, Russia, and South Africa could not be evaluated for molecular response due to logistical constraints; treated patients not
from these four countries were evaluable for molecular response. Molecular response was assessed at a central laboratory (Quest Diagnostics) using non-
nested real time PCR for the ratio of Bcr-Abl to Abl transcripts. MMR was categorized as a 3-log reduction from standardized baseline and included CMR
(undetectable Bcr-Abl transcript with a PCR sensitivity of 5 logs). To be considered a responder for MMR/CMR, the patient should also have had detectable
Bcr-Abl transcript levels at baseline or any time postbaseline, and have achieved/maintained a CCyR; patients with cytogenetic assessments not showing
CCyR on the same day of molecular assessment were not considered to have an MMR/CMR at that time. MMR was not assessed using the International
Scale because it was not widely available when the study was initiated.
c Evaluable patients must have had an adequate baseline hematologic assessment. The definition of CHR was standard [22]; hematologic response was
required to be confirmed and to last for 4 weeks, with peripheral blood and/or bone marrow documentation, and could be achieved during the study or
maintained from baseline for 5 weeks, unless otherwise noted within the table.
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bosutinib dose interruptions (15%) and reductions (6%). Few (n5 6)
patients discontinued bosutinib due to diarrhea. Antiemetics were used
in 45% and 33% of patients with nausea and vomiting, respectively.
Cardiac TEAEs (i.e., cardiac disorders and electrocardiogram inves-
tigations) were reported in 39 (14%) patients, including 6% with a
grade 3 cardiac event; few (n5 13 [5%]) had an event considered
Figure 1. Cumulative incidence curve for time to response adjusting for the competing risk of treatment discontinuation without response. Time to CHR (A), MCyR
(B), and MMR (D) was calculated among evaluable patients with a valid baseline assessment from the start date of therapy until the first date of attained/maintained
response (confirmed for CHR and unconfirmed for MCyR and MMR) or last nonmissing assessment date for those without a response or discontinuation. All treated
patients were evaluable for MMR except patients from sites in China, India, Russia, and South Africa, who were not assessed for molecular response. (C) Rates of
MCyR, including PCyR and CCyR, were cumulative by the defined time points for evaluable patients (IM-R, n5 186; IM-I, n580) who had an adequate baseline cyto-
genetic assessment and maintained/achieved their response. Abbreviations: CCyR, complete cytogenetic response; CHR, complete hematologic response; IM-I, ima-
tinib intolerant; IM-R, imatinib resistant; MCyR, major cytogenetic response; MMR, major molecular response; PCyR, partial cytogenetic response.
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RESEARCH ARTICLE Bosutinib in Imatinib-treated CP CML: 24 Months
treatment related by the investigator. The most common cardiac
events, irrespective of relationship, were atrial fibrillation and palpita-
tions (n5 7 each). Two patients discontinued treatment due to a car-
diac event, including grade 2 cardiac failure (considered drug related)
and grade 2 coronary artery disease, and 1 additional patient died of
unrelated cardiac failure 3 days after the patient’s last bosutinib dose.
During treatment, an increase from baseline in QTcF interval (i.e.,
corrected using Fridericia’s formula) of more than 60 msec (grade 2
toxicity) was detected in 1 imatinib-resistant patient, although the
patient’s QTcF interval remained within the normal range. A QTcF
interval exceeding 500 msec (grade 3 toxicity) was registered in a dif-
ferent imatinib-resistant patient on two separate occasions; the QTcF
interval returned to normal without treatment modification.
Maximum grade 3/4 hematologic laboratory abnormalities were
common among imatinib-resistant and imatinib-intolerant patients
(Table III). The median (range) time to first myelosuppression labora-
tory value was 8 days (2–589 days) for anemia, 21 days (2–841 days)
for thrombocytopenia, and 29 days (2–845 days) for neutropenia. Of
note, although 70 (24%) patients experienced grade 3/4 on-treatment
laboratory abnormalities of thrombocytopenia, only 3 imatinib-
resistant patients experienced hemorrhagic AEs (grade 1 conjunctival
hemorrhage lasting 8 days, grade 1 epistaxis lasting 1 day, and grade
3 subarachnoid hemorrhage lasting 16 days) in the context of grade
3/4 thrombocytopenia.
The most common nonhematologic laboratory abnormalities were
ALT and aspartate aminotransferase (AST) elevations (Table III),
with 82% and 91% of patients with events, respectively, experiencing
a maximum toxicity grade of 1/2. The median (range) duration of
ALT elevation from grade 3/4 to grade 0/1 was 36 days (11–596
days) for imatinib-resistant patients versus 19 days (15–170 days) for
Figure 1. Continued
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imatinib-intolerant patients; the duration from grade 2 to grade 0/1
was 29 days (3–288 days) versus 23.5 days (5–211 days), respectively.
Median (range) duration of AST elevation from grade 3/4 to grade 0/1
was 22 days (5–52 days) for imatinib-resistant patients versus 15 days
(7–170 days) for imatinib-intolerant patients; the duration from grade 2
to grade 0/1 was 15 days (7–169 days) versus 16 days (8–92 days).
Dose modifications due to TEAEs were common, with 65% of
imatinib-resistant patients and 83% of imatinib-intolerant patients
experiencing a temporary treatment interruption and 44% and 57%,
respectively, receiving a dose reduction. Thrombocytopenia was the
TEAE most frequently leading to treatment interruption (n5 66 [55% of
patients with thrombocytopenia]) and dose reduction (n5 43 [36% of
Figure 2. Duration of CHR (A), MCyR (B), and MMR (C). Duration of response was calculated among responders from the first date of response until con-
firmed loss of response, treatment discontinuation due to progressive disease or death, or death within 30 days of the last dose; patients without events
were censored at their last assessment visit. The probability of retaining response at 2 years was based on Kaplan–Meier estimates. Abbreviations: CHR,
complete hematologic response; IM-I, imatinib intolerant; IM-R, imatinib resistant; MCyR, major cytogenetic response; MMR, major molecular response.
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patients with thrombocytopenia]). The AEs most frequently leading to
bosutinib discontinuation were thrombocytopenia (5%), diarrhea (2%),
neutropenia (2%), and ALT elevation (2%; Supporting Information
Table SII).
The majority of both older (aged 65 years) and younger (aged
<65 years) patients experienced only maximum grade 1/2 events,
although certain types of TEAEs were reported more frequently
among older patients, particularly vomiting, constitutional symptoms,
pleural effusions, and dyspnea (Table II). In contrast, aminotransfer-
ase elevations, influenza, and abdominal pain were more common
among younger patients. Grade 3/4 hematologic laboratory abnormal-
ities among older and younger patients were thrombocytopenia (20%
and 25%, respectively), lymphopenia (20% and 13%), anemia (19%
and 12%), and neutropenia (13% and 18%). Dose interruptions and
reductions were observed among older (77% and 56%, respectively)
and younger (68% and 45%) patients; 30% of older patients and 20%
of younger patients discontinued bosutinib due to an AE (Table II).
Few patients in either group died within 30 days of their last dose
because of an AE (older, n5 1; younger, n5 2).
Long-term outcomes
Median PFS was not reached; the 2-year Kaplan–Meier estimate
of PFS was 81% (Fig. 3A). Disease progression included transforma-
tion to AP/BP CML, which occurred in 11 patients during bosuti-
nib treatment. Among imatinib-resistant patients, 4 patients
transformed to AP with a time to transformation ranging from 415
to 630 days after bosutinib initiation and 6 patients transformed to
BP with a time to transformation ranging from 42 to 476 days after
bosutinib initiation. One imatinib-intolerant patient transformed to
AP 246 days after bosutinib initiation; with continued bosutinib
treatment, this patient returned to CP and regained a confirmed
CHR.
Overall, 34 (12%) patients died during the study (ie, active treat-
ment phase plus 2-year posttreatment follow-up period), including
29 (15%) imatinib-resistant patients and 5 (6%) imatinib-intolerant
patients. Median OS was not reached; the 2-year Kaplan–Meier esti-
mate for OS was 91% (Fig. 3B). Disease progression was the most
common reason for death (n5 18 [6%]), followed by an AE (n5 10
[3%]); only one death was considered treatment-related (due to feb-
rile neutropenia 78 days after the last bosutinib dose). Five (2%)
patients (all imatinib-resistant) died within 30 days of their last bosu-
tinib dose. Of these, three deaths were attributed to AEs unrelated to
bosutinib (acute renal failure, pneumonia, cardiac failure) and two
deaths were attributed to disease progression.
Transformations to AP/BP CML as well as the 2-year Kaplan–
Meier estimates of PFS and OS were similar among older and
younger patients (Table II).
Among patients with 1 baseline Bcr-Abl kinase domain mutation
(n5 79) versus those without a baseline mutation (n5 133), the
2-year Kaplan–Meier estimates were generally lower for PFS (70%
[95% CI, 57–80] vs 86% [95% CI, 77–91]) and OS (81% [95% CI,
70–88] vs 95% [95% CI, 89–97]).
 Discussion
The current 2-year follow-up analysis of the phase 1/2 study of
bosutinib in imatinib-resistant and imatinib-intolerant CP CML con-
firms the previously reported clinical activity and tolerability of bosu-
tinib previously reported [22] and provides evaluation of longer-term
endpoints.
Consistent with the initial report for this study cohort [22], bosuti-
nib demonstrated high rates of cumulative MCyR in imatinib-resistant
(58%; including a 46% CCyR rate) and imatinib-intolerant (61%;
including a 54% CCyR rate) patients. Among patients without a CCyR
at baseline, 57% of both imatinib-resistant and imatinib-intolerant
patients achieved an MCyR. The rates of CHR (85%) and MMR (35%)
were also high in this previously treated population. Notwithstanding
differences in study design and patient populations, the response rates
in the current study are similar to those observed in studies with other
second-generation TKIs (dasatinib, nilotinib) after a minimum 2-year
Figure 2. Continued
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TABLE II. Summary of Results for Older versus Younger Patients
Parameter Older patients (65 y) (n564) Younger patients (<65 y) (n5224)
Median (range) age, y 70 (65–91) 48 (18–64)
ECOG performance status,a n (%)
0 39 (61) 181 (81)
1 25 (39) 41 (18)
2 0 1 (<1)
Median (range) time since CML diagnosis, y 5.5 (0.1–13.7) 3.2 (0.1–15.1)
Key baseline medical conditions, n (%)
Gastrointestinal disorders 38 (59) 77 (34)
Vascular disorders 31 (48) 52 (23)
Metabolism disorders 27 (42) 70 (31)
Diabetes mellitus 2 (3) 7 (3)
Musculoskeletal disorders 27 (42) 60 (27)
Blood/lymphatic disorders 26 (41) 67 (30)
Cardiac disordersb 25 (39) 23 (10)
Nervous system disorders 23 (36) 31 (14)
Respiratory disorders 19 (30) 31 (14)
Endocrine disorders 11 (17) 16 (7)
Hepatobiliary disorders 4 (6) 19 (9)
Median (range) no. of baseline medications 4 (1–14) 2 (1–16)
Median (range) duration of bosutinib, mo 13.8 (0.3–48.9) 22.1 (0.2–60.8)
Median (range) follow-up, mo 33.8 (1.0–53.0) 31.7 (0.6–66.0)
Cytogenetic response,c n (%) [95% CI]
Evaluable patients 62 204
MCyR 33 (53) [40–66] 124 (61) [54–68]
CCyR 29 (47) [34–60] 99 (49) [42–56]
Probability of retaining MCyR at 2 yearsd 72% [52–85] 78% [69–84]
Hematologic response,e n (%) [95% CI]
Evaluable patients 64 223
CHR 52 (81) [70–90] 192 (86) [81–90]
Probability of retaining CHR at 2 yearsd 65% [48–77] 74% [67–80]
Non-hematologic TEAEs with 8% difference between age groups
Vomiting 29 (45) 77 (34)
Fatigue 23 (36) 44 (20)
Decreased appetite 17 (27) 23 (10)
Weight decreased 14 (22) 9 (4)
Asthenia 13 (20) 23 (10)
Nasopharyngitis 12 (19) 24 (11)
Dyspnea 12 (19) 13 (6)
Peripheral edema 10 (16) 13 (6)
Increased ALT 9 (14) 53 (24)
Pleural effusion 9 (14) 6 (3)
Increased AST 8 (13) 46 (21)
Increased lipase 8 (13) 11 (5)
Chills 8 (13) 8 (4)
Increased blood creatinine 8 (13) 5 (2)
Abdominal pain 7 (11) 60 (27)
Influenza 1 (2) 22 (10)
Dose interruption due to a TEAE, n (%) 49 (77) 153 (68)
Dose reduction due to a TEAE, n (%) 36 (56) 101 (45)
Discontinuation due to an AE, n (%) 19 (30) 47 (21)
Death within 30 days of last dose due to an AE, n (%) 1 (2) 2 (1)
Transformation to AP/BP CML, n 2 9
PFS at 2 yearsd [95% CI] 76% [60–87] 82% [75–87]
OS at 2 yearsd [95% CI] 87% [75–93] 92% [87–95]
Abbreviations: AE, adverse event; ALT, alanine aminotransferase; AP, accelerated phase; AST, aspartate aminotransferase; BP, blast phase; CCyR, complete
cytogenetic response; CHR, complete hematologic response; CML, chronic myeloid leukemia; ECOG, Eastern Cooperative Oncology Group; FISH, fluores-
cence in situ hybridization; MCyR, major cytogenetic response; OS, overall survival; PCyR, partial cytogenetic response; PFS, progression-free survival; Ph1,
Philadelphia chromosome-positive; TEAE, treatment-emergent adverse event.
a ECOG Performance Status was missing for 1 younger, imatinib-intolerant patient.
b The most common cardiac events at baseline (3 patients) were coronary artery disease (older, n5 6; younger, n5 1), myocardial infarction (n5 5; n5 1,
respectively), acute myocardial infarction (n5 2; n5 3), arrhythmia (n53; n52), cardiomyopathy (n53; n52), and palpitations (n52; n52).
c Evaluable patients must have had an adequate baseline cytogenetic assessment. Cytogenetic response [27] was determined using standard cytogenetics
(G-band karyotype) with 20 metaphases counted for postbaseline assessments; if <20 metaphases were available post-baseline, FISH analysis of bone
marrow aspirate with 200 cells for the presence of Bcr-Abl fusion gene was used. MCyR included PCyR (1–35% Ph1 metaphases) and CCyR (0% Ph1
metaphases; <1% if using FISH). Cytogenetic response could be achieved during the study or maintained from baseline for 4 weeks.
d Probabilities at 2 years were based on Kaplan–Meier estimates.
e Evaluable patients must have had an adequate baseline hematologic assessment. The definition of CHR was standard [22]; hematologic response was
required to be confirmed and to last for 4 weeks, with peripheral blood and/or bone marrow documentation, and could be achieved during the study or
maintained from baseline for 5 weeks.
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follow-up. In a phase 3 dose-optimization study, 63% of patients who
had received dasatinib 100 mg/day after imatinib failure (n5 167)
achieved/maintained an MCyR (including a 50% CCyR rate), and 92%
of patients achieved/maintained a CHR [12]. In a phase 2 study of
nilotinib 800 mg/day after imatinib failure (n5 321), MCyR was
achieved by 59% of patients (including a 44% CCyR rate) [8]. Com-
pared with the present study, responses to dasatinib and nilotinib were
achieved more rapidly, with median times to MCyR <3 months [8,12];
however, this could be explained by the visit schedule, as CP CML
patients in the current bosutinib study were not required to have their
first cytogenetic assessment until month 3.
Responses to bosutinib were durable, with Kaplan–Meier estimates
of 72% for retaining a CHR, 77% for retaining an MCyR, and 82% for
retaining an MMR among all responders at 2 years; these rates were
higher among imatinib-intolerant patients (82%, 88%, and 91%, respec-
tively). The durability of response observed with bosutinib is compara-
ble to that reported for dasatinib 100 mg/day (MCyR retained by 87%)
[12] and nilotinib 800 mg/day (MCyR retained by 77%) [8] at 2 years
in patients with CP CML following imatinib failure.
The results of the present study also confirm previous reports
[22,23,26] indicating that bosutinib is associated with a manageable
toxicity profile in patients with CP CML. The most common toxic-
ities were transient, low-grade gastrointestinal AEs that arose early
during treatment, liver function test abnormalities, and hematologic
toxicity. The overall incidence of cardiac AEs considered related to
bosutinib treatment was low (5%); this observation is consistent with
data-reported treatment-related cardiac AEs in the phase 3 study of
bosutinib (4%) versus imatinib (3%) in newly diagnosed patients with
CP CML after 12 months follow-up [26]. The number of patients
reporting a specific AE has increased only minimally from the prior
report of this patient cohort [22], suggesting the toxicity profile is
well-established and has not changed with this extended follow-up.
Further, events were typically manageable with concomitant medica-
tion and/or bosutinib dose modification, were self-limited and reversi-
ble, and rarely resulted in treatment discontinuation. Of note, the
safety profile of bosutinib remains somewhat distinct from that of
imatinib, dasatinib, and nilotinib in patients with CP CML, although
all TKIs are characterized by a frequent occurrence of manageable
hematologic events as well as the common need for dose modification
to help manage certain toxicities [7–10,12,26].
With bosutinib, 2-year PFS and OS estimates were 81% and 91%,
respectively. Considering all the limitations of cross-trial comparisons,
these estimates appear similar to the 2-year data for dasatinib 100 mg/
day (PFS, 80%; OS, 91%) [12] and nilotinib 800 mg/day (PFS, 64%; OS,
87%) [8]. Of note, because 55% of patients in the current study had dis-
continued bosutinib as of the minimum 2-year follow-up, poststudy
TABLE III. Treatment-Emergent Adverse Events and Laboratory Abnormalities
Event, n (%)
Imatinib-resistant (n5 200) Imatinib-intolerant (n5 88) Total (n5288)
All grades Grade 3/4 All grades Grade 3/4 All grades Grade 3/4
Nonhematologic TEAEsa
Diarrhea 168 (84) 17 (9) 75 (85) 11 (13) 243 (84) 28 (10)
Nausea 84 (42) 0 45 (51) 4 (5) 129 (45) 4 (1)
Vomiting 70 (35) 3 (2) 36 (41) 8 (9) 106 (37) 11 (4)
Rash 63 (32) 17 (9) 36 (41) 10 (11) 99 (34) 27 (9)
Pyrexia 54 (27) 1 (1) 14 (16) 0 68 (24) 1 (<1)
Abdominal pain 45 (23) 2 (1) 22 (25) 2 (2) 67 (23) 4 (1)
Fatigue 45 (23) 1 (1) 22 (25) 2 (2) 67 (23) 3 (1)
Elevated ALT 41 (21) 13 (7) 21 (24) 8 (9) 62 (22) 21 (7)
Upper abdominal pain 40 (20) 1 (1) 17 (19) 0 57 (20) 1 (<1)
Cough 44 (22) 1 (1) 13 (15) 0 57 (20) 1 (<1)
Elevated AST 36 (18) 6 (3) 18 (21) 5 (6) 54 (19) 11 (4)
Headache 30 (15) 0 18 (21) 0 48 (17) 0
Arthralgia 27 (14) 0 13 (15) 1 (1) 40 (14) 1 (<1)
Decreased appetite 27 (14) 2 (1) 13 (15) 0 40 (14) 2 (1)
Asthenia 22 (11) 5 (3) 14 (16) 0 36 (13) 5 (2)
Back pain 16 (8) 0 17 (19) 0 33 (12) 0
Nasopharyngitis 24 (12) 0 12 (14) 0 36 (13) 0
Constipation 18 (9) 0 15 (17) 1 (1) 33 (12) 1 (<1)
Oropharyngeal pain 22 (11) 0 8 (9) 0 30 (10) 0
Hematologic laboratory abnormalitiesb
Thrombocytopenia 131 (66) 42 (21) 62 (70) 28 (32) 193 (67) 70 (24)
Anemia 182 (91) 23 (12) 76 (86) 16 (18) 258 (90) 39 (14)
Leukopenia 101 (51) 14 (7) 46 (52) 9 (10) 147 (51) 23 (8)
Neutropenia 97 (49) 28 (14) 45 (51) 21 (24) 142 (49) 49 (17)
Nonhematologic laboratory abnormalitiesb
Elevated ALT 110 (55) 20 (10) 58 (66) 10 (11) 168 (58) 30 (10)
Elevated AST 97 (49) 7 (4) 48 (55) 6 (7) 145 (50) 13 (5)
Hypophosphatemia 89 (45) 19 (10) 36 (41) 6 (7) 125 (43) 25 (9)
Hypocalcemia 82 (41) 5 (3) 41 (47) 6 (7) 123 (43) 11 (4)
Hyperglycemia 85 (43) 4 (2) 27 (31) 4 (5) 112 (39) 8 (3)
Elevated creatinine 74 (37) 2 (1) 36 (41) 0 110 (38) 2 (1)
Elevated alkaline phosphatase 69 (35) 0 35 (40) 0 104 (36) 0
Low bicarbonate 58 (29) 0 30 (34) 1 (1) 88 (31) 1 (<1)
Elevated lipase 52 (26) 16 (8) 31 (35) 8 (9) 83 (29) 24 (8)
Hypermagnesemia 50 (25) 15 (8) 27 (31) 18 (21) 77 (27) 33 (12)
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; TEAE, treatment-emergent adverse event.
Toxicities were graded for severity using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0.
a Includes TEAEs reported for 10% of patients.
b Includes on-treatment laboratory abnormalities reported for 30% of patients (all grades) and grade 3/4 laboratory abnormalities reported for 5% of
patients.
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therapy may have influenced the OS estimates (evaluated on treatment
and during the 2-year follow-up period); similar influences were also
incorporated into the OS estimates for dasatinib (41% discontinued)
[12] and nilotinib (61% discontinued) [8] as of the minimum 2-year
follow-up. Longer follow-up would be required to further evaluate the
effect of bosutinib on long-term survival.
Figure 3. PFS (A) and OS (B). PFS was calculated for the all-treated population from the start date of therapy until treatment discontinuation due to disease
progression (as assessed by the investigator; including transformation to AP or BP CML) or death, or death within 30 days of the last dose; patients without
events were censored at their last assessment visit. OS was calculated for the all-treated population from the start date of therapy to the date of death due
to any cause; patients without events were censored at the last contact (patients were followed up for 2 years after treatment discontinuation). PFS and OS
at 1 and 2 years were based on Kaplan–Meier estimates. Abbreviations: AP, accelerated phase; BP, blast phase; CML, chronic myeloid leukemia; IM-I, imatinib
intolerant; IM-R, imatinib resistant; OS, overall survival; PFS, progression-free survival.
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A favorable benefit-to-risk profile was observed for bosutinib in
older and younger patients, although specific outcomes were some-
what different between the age groups.
In summary, bosutinib demonstrated durable clinical activity and
manageable toxicity as second-line therapy in patients with CP
CML resistant or intolerant to imatinib, with results generally com-
parable to those reported for dasatinib and nilotinib as second-line
therapy [8,12]. Bosutinib is also being evaluated in patients with CP
CML following resistance or intolerance to imatinib plus dasatinib
and/or nilotinib [23] and in patients with previously treated AP or
BP CML [24].
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